Leflunomide
- Generic Name
- Leflunomide
- Brand Names
- Arava, Leflunomide medac, Leflunomide Zentiva (previously Leflunomide Winthrop), Leflunomide ratiopharm
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9F3N2O2
- CAS Number
- 75706-12-6
- Unique Ingredient Identifier
- G162GK9U4W
- Background
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
- Indication
For the management of the signs and symptoms of active rheumatoid arthritis (RA) to improve physical function and to slow the progression of structural damage associated with the disease. Has also been used for the prevention of acute and chronic rejection in recipients of solid organ trasnplants and is designated by the FDA as an orphan drug for this use.
- Associated Conditions
- Juvenile Idiopathic Arthritis (JIA), Rheumatoid Arthritis
- Associated Therapies
- -
To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)
- Conditions
- Interventions
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 546
- Registration Number
- NCT01709578
- Locations
- 🇺🇸
Investigational Site Number 840018, Idaho Falls, Idaho, United States
🇺🇸Investigational Site Number 840058, Columbia, South Carolina, United States
🇺🇸Investigational Site Number 840124, Clarksburg, West Virginia, United States
Leflunomide Versus Sulfasalazine/Methotrexate in Rheumatoid Arthritis:an Ultrasound/Magnetic Resonance Imaging Study
- Conditions
- Interventions
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Singapore General Hospital
- Target Recruit Count
- 1
- Registration Number
- NCT01659242
- Locations
- 🇸🇬
Singapore General Hospital, Singapore, Singapore
Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood
- Conditions
- Interventions
- First Posted Date
- 2012-06-14
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Chinese Academy of Sciences
- Target Recruit Count
- 10
- Registration Number
- NCT01619176
- Locations
- 🇨🇳
Shanghai GuangHua Hospital of integrated traditional and western medicine, Shanghai, Shanghai, China
Disease-Modifying Antirheumatic Drugs Cycle Combination Therapy Research
- First Posted Date
- 2012-06-12
- Last Posted Date
- 2012-06-14
- Lead Sponsor
- Shanxi Medical University
- Target Recruit Count
- 500
- Registration Number
- NCT01617590
- Locations
- 🇨🇳
rheumatism department,Second hospital of Shanxi medical university, TaiYuan, Shanxi, China
Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
- First Posted Date
- 2012-06-05
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT01611675
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in Combination With a DMARD in Patients With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2010-10-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT01225393
Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.
- Conditions
- Interventions
- First Posted Date
- 2010-07-30
- Last Posted Date
- 2019-01-22
- Lead Sponsor
- P. Verschueren
- Target Recruit Count
- 400
- Registration Number
- NCT01172639
- Locations
- 🇧🇪
Reuma instituut Hasselt, Hasselt, Belgium
🇧🇪ZNA Jan Palfijn, Merksem, Belgium
🇧🇪Henri Serruys ziekenhuis, Oostende, Belgium
Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2010-08-11
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01172002
- Locations
- 🇨🇳
RenJi Hospital, ShangHai, Shanghai, China
Leflunomide Associated With Topical Corticosteroids for Bullous Pemphigoid
- Conditions
- First Posted Date
- 2008-12-04
- Last Posted Date
- 2008-12-04
- Lead Sponsor
- University Hospital, Limoges
- Target Recruit Count
- 54
- Registration Number
- NCT00802243
- Locations
- 🇫🇷
Bordeaux University Hospital, Pessac, France
🇫🇷Toulouse University Hospital, Toulouse, France
🇫🇷Limoges University Hospital, Limoges, France
BK Viremia After Renal Transplantation
- Conditions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2009-02-06
- Lead Sponsor
- Karolinska University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT00684372
- Locations
- 🇸🇪
Karolinska University Hospital, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.